Click bait

GlaxoSmithKline plc is developing click chemistry-based systems to pinpoint and quantify how drug candidates target DNA sequences, protein complexes and disease sites. The company believes the "click-probes" could slash failure rates in drug development by validating target engagement.

The idea is that click chemistry -- which covalently links chemical groups without disrupting nearby biochemical reactions -- can be exploited to catch and report molecular interactions in situ, providing a snapshot of where candidate drugs are binding and how that influences surrounding molecules...